Brokerage Upgrade
Motilal Oswal has revised its stance on Indegene, upgrading the stock from a Neutral rating to Buy. The brokerage has assigned a target price of INR 708 to the shares. This valuation is derived from a multiple of 25 times the estimated earnings per share (EPS) for the fiscal year 2028 (FY28E).
Operational Efficiency for Global Pharma
The research report highlights the strategic value Indegene provides to global life science and pharmaceutical companies. These firms increasingly prefer onboarding external agencies to manage operational complexities. By leveraging Indegene, companies can reduce operational costs and accelerate their go-to-market strategies for new drugs.
A key advantage cited is the ability to access specialized global talent and manage significant spikes in content volume. Drug launches often require a surge in marketing and regulatory content, followed by periods of lower activity. External agencies like Indegene allow companies to scale teams up or down instantly, avoiding the friction and costs associated with internal hiring or layoffs.
Streamlining Regulatory Compliance
The report notes that internal medical, legal, and regulatory (MLR) reviews often create bottlenecks, delaying campaigns by weeks or months. Indegene addresses this by streamlining processes such as tagging, referencing, and pre-review preparation.
Furthermore, global drug launches require content tailored to specific country laws. Indegene utilizes local compliance experts who understand the specific requirements of various government health departments. By maintaining teams across different time zones, including the US, Europe, and India, the agency enables around-the-clock drafting, formatting, and pre-vetting of content. This approach significantly shortens approval cycles for global clients.
Investment Perspective
The upgrade reflects the brokerage's view that Indegene's model of providing flexible, compliant, and scalable content solutions is well-positioned to benefit from the ongoing outsourcing trends in the global pharmaceutical sector. The target price suggests potential upside for investors based on the firm's projected earnings growth through FY28.